Facts
as of Nov 17, 2026
At Climb Bio, our team has a knack for seeing what no one else sees—and a drive to achieve results no one expects.
It is hiring: 6 open roles, 2 of them posted in the last 30 days.
- Legal name
- Climb Bio, Inc.
- Headquarters
- Boston, United States
- Founded
- 2018
- Employees
- 51-200estimated range
- Legal entities
- 2 in 1 countries
- Listing
- NASDAQ: CLYM
- Open roles
- 6Alion job postings
- Register numbers
- NAME climb bio inc
- Website
- climbbio.com
As of Nov 17, 2026, Alion lists 6 open roles at Climb Bio. Climb Bio is headquartered in Boston, United States. It was founded in 2018. It has raised $363.2M in 7 funding rounds. The latest round is Venture - Series Unknown of $110.1M, announced in 2026.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Legal entity active
Climb Bio, Inc.
Not checked
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Hiring steadily, with new roles every week.
Biotech is the largest family, 33 of open roles.
2Posted in 30 days33% of open roles are fresh
0%Remote roles0 of 6
1Hiring offices
Can they hire you from United States?by your location
Likely
6 open roles are in your country: you apply locally, no move needed.
United States6On site
Remote, from elsewhere0Rare
No posting offers visa sponsorship. Remote roles: 0.
Alion signals0-100
Demand13
Pay44
Your chance44
How badly they need people, whether they pay, how realistic getting in is.
Where the openings areshare of open roles · trend
Biotech33▲
Leadership17▲
HR17▲
Legal17▲
Management17▲
Degree asked
Bachelor's Degree 75%Doctoral Degree (PhD) 25%
4 postings state a degree.
Benefits named in postingsshare of open roles
401k plan6100%
Equity583%
Stock options117%
Life insurance117%
Contract type
Full-Time 6
Visa sponsorship: none statedRelocation: none stated
Source: the company's careers site, read by Alion several times a day; market medians from all open roles of the same family
Pay
What its postings pay, by level.
$235kMedian
$215k – $260kTypical rangeUSD a year
$260kHighest paying roleDirector, Legal Operations & Contracts
Source: the pay stated in the company's postings, normalised to USD a year
Footprint
Hiring in 1 city in 1 country.
1Cities
1Countries
WellesleyBusiest site
Source: office addresses in postings and company registers
Financials
Funding rounds, investors and revenue on record.
$363.2MTotal raised
Venture - Series UnknownLatest round
7Rounds and grants
Money by yearUSD, rounds and grants
2026$110.1M1 record
2024$161.9M2 records
2021$60M1 record
2020$5M1 record
2019$26.3M2 records
Largest rounds and grants
Sources: funding announcements, grant and company registers
Tech stack
Technologies named in job postings at Climb Bio over the last 12 months, by layer, with the share of postings for each.
3Technologies in use
3Postings analysed
64/100Stack modernity
Sign in to see how your skills match this stackSign In
Source: the technologies named in the company's postings and on its site
Milestones
Each milestone is dated by its source: registers, filings, the press
Newsroom
Sep 32026
News · markets.businessinsider.com
29-day half-life Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks CLYM116 ...
Aug 62026
Press release · Nasdaq
--Climb Bio, Inc., a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the second quar…
May 72026
Press release · The Manila Times
Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development
Mar 25, 20252025
Press release · streetinsider.com
Jan 8, 20252025
News · Nasdaq
Climb Bio licenses CLYM116, an anti-APRIL antibody, expanding its immune-mediated disease pipeline, with preclinical data expected in 2025.
Sources: the outlets named on each headline, each story once